Equities Analysts Set Expectations for DexCom, Inc.’s Q1 2018 Earnings (DXCM)

DexCom, Inc. (NASDAQ:DXCM) – Research analysts at Oppenheimer issued their Q1 2018 earnings per share estimates for shares of DexCom in a research note issued on Monday. Oppenheimer analyst S. Lichtman expects that the medical device company will post earnings per share of ($0.32) for the quarter. Oppenheimer currently has a “Buy” rating and a $67.00 price target on the stock. Oppenheimer also issued estimates for DexCom’s Q3 2018 earnings at ($0.04) EPS, Q4 2018 earnings at $0.12 EPS and FY2019 earnings at ($0.06) EPS.

Several other analysts have also issued reports on the company. Zacks Investment Research lowered DexCom from a “hold” rating to a “sell” rating in a research note on Tuesday, October 24th. Morgan Stanley dropped their price objective on DexCom from $72.00 to $52.00 and set a “neutral” rating on the stock in a research note on Friday, November 3rd. TheStreet lowered DexCom from a “c-” rating to a “d+” rating in a research note on Wednesday, October 25th. BidaskClub upgraded DexCom from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, December 12th. Finally, Northland Securities restated a “sell” rating and issued a $40.00 price objective on shares of DexCom in a research note on Tuesday, January 16th. Three investment analysts have rated the stock with a sell rating, six have given a hold rating and fourteen have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $67.44.

Shares of DexCom (NASDAQ:DXCM) opened at $54.69 on Tuesday. The company has a debt-to-equity ratio of 0.84, a current ratio of 5.86 and a quick ratio of 5.50. The stock has a market capitalization of $4,750.00, a P/E ratio of -95.95 and a beta of 0.21. DexCom has a 52 week low of $42.62 and a 52 week high of $86.32.

In other news, Director Barbara Kahn sold 3,000 shares of the company’s stock in a transaction that occurred on Monday, November 20th. The stock was sold at an average price of $54.58, for a total value of $163,740.00. Following the transaction, the director now owns 4,353 shares of the company’s stock, valued at $237,586.74. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Andrew K. Balo sold 3,245 shares of the company’s stock in a transaction that occurred on Monday, December 11th. The shares were sold at an average price of $61.23, for a total value of $198,691.35. The disclosure for this sale can be found here. Insiders sold 48,140 shares of company stock worth $2,743,281 in the last ninety days. 1.70% of the stock is owned by company insiders.

A number of large investors have recently modified their holdings of the stock. The Manufacturers Life Insurance Company grew its position in DexCom by 12.2% during the second quarter. The Manufacturers Life Insurance Company now owns 3,254 shares of the medical device company’s stock worth $238,000 after buying an additional 354 shares in the last quarter. Advisor Group Inc. grew its position in DexCom by 104.9% during the second quarter. Advisor Group Inc. now owns 1,635 shares of the medical device company’s stock worth $119,000 after buying an additional 837 shares in the last quarter. Wedbush Securities Inc. grew its position in DexCom by 24.2% during the fourth quarter. Wedbush Securities Inc. now owns 5,589 shares of the medical device company’s stock worth $321,000 after buying an additional 1,089 shares in the last quarter. Dimensional Fund Advisors LP grew its position in DexCom by 0.9% during the third quarter. Dimensional Fund Advisors LP now owns 127,769 shares of the medical device company’s stock worth $6,247,000 after buying an additional 1,095 shares in the last quarter. Finally, Stifel Financial Corp grew its position in DexCom by 15.2% during the third quarter. Stifel Financial Corp now owns 8,567 shares of the medical device company’s stock worth $422,000 after buying an additional 1,129 shares in the last quarter.

TRADEMARK VIOLATION WARNING: “Equities Analysts Set Expectations for DexCom, Inc.’s Q1 2018 Earnings (DXCM)” was first published by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of U.S. & international copyright law. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2018/02/13/equities-analysts-set-expectations-for-dexcom-inc-s-q1-2018-earnings-dxcm.html.

DexCom Company Profile

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Earnings History and Estimates for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply